WGS Earnings Prediction
The chart below shows how WGS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, WGS sees a -6.19% change in stock price 10 days leading up to the earnings, and a -3.07% change 10 days following the report. On the earnings day itself, the stock moves by +6.18%. This data can give you a slight idea of what to expect for the next quarter's release.
WGS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
95.64M
66.57%
24.41%
Gross Margin
69.22%
29.24%
11.25%
Operating Margin
9.21%
122.35%
-191.01%
Net Margin
5.69%
112.68%
-152.64%
EPS
0.20
120.20%
-164.52%
No Data Available
WGS Earnings Analysis
GeneDx Holdings Corp Corporation (WGS.O) Earnings Conference Call
Positive
Earnings Per Share Surprise: GeneDx Holdings Corp. reported an impressive EPS of $0.62, significantly surpassing expectations of $0.04.
Record Revenue Achievement: The company achieved revenues exceeding $95 million in Q4 2024, with exome and genome revenues growing 101% year-over-year and 31% sequentially, contributing $78.8 million this quarter.
Gross Margin Expansion: Gross margins expanded to 70% in Q4 2024, up from 56% a year ago, indicating improved operational efficiency.
2025 Revenue Guidance: GeneDx is setting guidance for 2025 with expected revenues between $350 million to $360 million, anticipating at least 30% growth in exome and genome volume and revenue.
Reimbursement Rate Improvement: The company has successfully reduced the average reimbursement rate for exome and genome tests to approximately $3,500, up from $2,500 a year ago, reflecting improved payment processes.
Adjusted Gross Profit Surge: GeneDx's operational strength has led to an adjusted gross profit of $66.9 million in Q4 2024, a 106% increase compared to the prior year.
Quarterly Profitability Achievement: The company reported a total adjusted net income of $16.8 million for Q4 2024, marking its second consecutive quarter of profitability.
Strong Cash Position: GeneDx has a strong cash position with $142.2 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2024.
Market Expansion Strategy: The company is expanding its market presence by targeting new patient populations and enhancing its product offerings, including the launch of an ultraRapid whole genome sequencing product that delivers results in as soon as 48 hours.
Negative
Strategic Market Exit: GeneDx is exiting the hereditary cancer testing market in 2025, indicating a strategic shift away from a previously core business area.
Cost Reduction Challenges: Despite strong revenue growth, the company acknowledges that there is still work to do in reducing costs per test, suggesting ongoing operational challenges.
Market Presence Development: The company’s growth in the NICU and outpatient settings is starting from near zero, indicating a lack of established market presence in these areas.
Reimbursement Rate Vulnerabilities: The average reimbursement rate for exome and genome testing, while improved, still relies heavily on reduced denials, highlighting potential vulnerabilities in revenue stability.
Adjusted Net Income Concerns: The reported adjusted net income includes a significant one-time benefit from a multiyear appeal win, which may not be sustainable in future quarters, raising concerns about ongoing profitability.
Competitive Innovation Strategy: The company is facing a competitive landscape where it must continuously innovate and improve customer experience to maintain its market position.
WGS FAQs
How does WGS typically perform around its earnings report dates?
Is GeneDx Holdings Corp (WGS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
WGS Earning Call Sentiment
GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2024 Earnings Call Transcript
WGS.O
-3.89%Positive
The earnings call presents strong financial performance with 101% revenue growth, improved gross margins, and positive cash flow. Despite risks in market expansion and a secondary offering, raising guidance for revenue and gross margins signals confidence. The Q&A indicates proactive management in refining processes and expanding opportunities, though some uncertainties remain. Overall, the financial results and optimistic guidance outweigh potential risks, suggesting a positive stock price movement.
